The influence of age and health status for outcomes after mid-urethral sling surgery – a Swedish national register study

Gyhagen J1, Åkervall S2, Larsudd-Kåverud J2, Molin M3, Milsom I2, Wagg A4, Gyhagen M2

Research Type

Clinical

Abstract Category

Geriatrics / Gerontology

Abstract 168
Geriatrics/Gerontology
Scientific Podium Short Oral Session 10
Thursday 8th September 2022
15:57 - 16:05
Hall G1
Female Gerontology Stress Urinary Incontinence Surgery Incontinence
1. Department of Geriatrics, Dalen Hospital, Stockholm, Sweden, 2. Gothenburg Continence Research Centre, Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, 3. Statistical Consultancy Group, Gothenburg, Sweden, 4. Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada
In-Person
Presenter
J

Jennie Larsudd-Kåverud

Links

Abstract

Hypothesis / aims of study
Despite being safe and less invasive than traditional surgery for stress urinary incontinence (SUI), proportion of mid-urethral sling surgeries performed in older women has decreased [1]. SUI prevalence increases with age and incurs a high cost for the individual and society [2]. However, evidence of the efficacy of mid-urethral sling surgery in older women and women with a significant disease burden is limited. This study in women, grouped according to the American Society of Anesthesiologists Physical Status (ASA) class, examined the influence of chronological age and disease burden on satisfaction, improvement, cure, and adverse events at a 1-year follow-up following mid-urethral sling surgery.
Study design, materials and methods
This cohort study was based on the Swedish National Quality Register of Gynecological surgery (GynOp) [3]. 5200 women aged 55-94 years had surgery (2010-2017) and were divided into three age cohorts: 55-64, 65-74, and 75-94 years of age. The preoperative questionnaire included height, weight, parity, prior abdominal and gynecological surgery, comorbidity, and physical performance. An anesthesiologist performed an ASA classification at the time of the intervention. Women in ASA class 1-2 (healthy or mild systemic disease) were categorized as healthy, and those with ASA class 3-4 (severe systemic disease with/ without a constant threat to life) were classified as having a significant disease burden. One year postoperatively, women were asked to complete a questionnaire about cure (defined here as SUI never or 1-4 times per month), change in urinary frequency, satisfaction, impact, and adverse events after surgery. Given the size of the study cohorts, an alpha level of 0.05, and a power value of 80%, the minimum significant difference in prevalence of outcomes was 5% in pairwise comparisons between groups using Fisher’s exact test for the analysis.
Results
In Sweden 2007-2017, the proportion of mid-urethral sling surgeries performed in women ≥75 years more than halved (Trend P<0.0001). The response rate to the 1-year postoperative questionnaire was similar among age groups (>86%), resulting in a study population of 4581 women. The overall estimated probability of cure, improvement of SUI, and satisfaction with the procedure was similar and decreased by OR10yr 0.48 for cure to OR10yr 0.54 for satisfaction (all P<0.0001). Women with a significant disease burden had lower rates of cure and satisfaction compared with healthy women (65.5% vs. 83.7% and 65.7% vs. 80.6%, both P<0.0001). Women with prior incontinence surgery had a lower cure rate than first-time surgery (73.5% versus 84.3%, P<0.0001) (Figure 1). A low preoperative rate of leakage was associated with being unchanged or worse at follow-up (P<0.0001). Cure and satisfaction were also lower in women with diabetes (P<0.0001). Younger (55-74 years) and older women (≥75 years) were equally satisfied if they experienced a decrease of at least one step in the frequency of leakage. Older age was more likely to be associated with de novo urgency (P=0.0022) and nocturia ≥2 (P<0.0001), and women with a significant health burden experienced greater de novo urgency (P=0.0018). Body mass index ≥30 (kg/m2) was associated with a higher rate of de novo urgency and nocturia ≥2/night (P<0.0214 and P<0.015) (Figure 2). Adverse events, readmission, and 30-day mortality rates were low.
Interpretation of results
Older age, prior incontinence surgery, and a significant disease burden were associated with a less satisfactory outcome, whereas adverse events were few and similar across ages. Disease burden seemed more important than chronological age for all outcomes. Older women and those with a significant disease burden were satisfied with the procedure if they experienced a reduction of leakage episodes.
Concluding message
Despite mid-urethral sling surgery in older women and those with significant disease burden being associated with a lower cure rate and less satisfactory outcome, a majority of the women were satisfied provided they experienced a reduction in incontinence episodes.
Figure 1 Figure 1. The probability of cure of stress urinary incontinence A. According to age and ASA-class B. According to age and prior surgery
Figure 2 Figure 2. Remission and de novo lower urinary tract symptoms
References
  1. Gibson W, Wagg A. Are older women more likely to receive surgical treatment for stress urinary incontinence since the introduction of the mid-urethral sling? An examination of Hospital Episode Statistics data. BJOG 2016;123:1386–1392.
  2. Milsom I, Altman D, Cartwright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP), and anal (AI) incontinence. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence 6th ed. Paris: Health Publications Ltd; 2016: pp 17–24.
  3. Gynaecological Surgery. The Swedish National Quality Register of Gynaecological Surgery (GynOp). Available at: https://skr.se/en/kvalitetsregister/hittaregister/registerarkiv/gynekologiskaoperationer.44199.html. Accessed January 1, 2022.
Disclosures
Funding MG: speakers fee from Svenska Cellulosa Aktiebolaget (SCA), Essity, and Astellas Pharma. IM: lectures fee from SCA and Essity, Astellas Pharma, Pfizer, Pierre Fabre Laboratories, and Allergan. AW: research support and speaker honoraria from Essity, Urovant Sciences & Pfizer Corp. Remaining authors: no conflict of interest. Grants from the Swedish state financed the study under the agreement between the Swedish Government and the county councils, the ALF-agreement (No. ALFGBG-966115). Clinical Trial Yes Public Registry No RCT No Subjects Human Ethics Committee • Ethical approvals for this study were obtained from the Regional Ethical Review Board in Gothenburg (reference no 345-17; 15 June 2017) and Swedish Ethical Review Authority (reference no: 2020-01359; 6 May 2020). Helsinki Yes Informed Consent Yes
Citation

Continence 2S2 (2022) 100280
DOI: 10.1016/j.cont.2022.100280

18/04/2024 04:01:33